Biodesix (BDSX) Stock Price & Analysis

367 Followers

BDSX Stock Chart & Stats

$10.12$0.10(1.00%)

At close: Nov 11 4:00 PM EST

Day’s Range: $9.68 - $11.30
52-Week Range: $5.26 - $31.97
Previous Close: $10.02
Volume: N/A
Average Volume (3M): 201.03K
Market Cap: $111.11M
Enterprise Value: $361.92M
Total Cash (Recent Filing): $28.41M
Total Debt (Recent Filing): $72.44M
Price to Earnings (P/E): ―
Beta: 0.65
Next Earnings: Mar 16, 2027 (Est.)
EPS Estimate: -0.63
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Bulls Say, Bears Say

Bulls Say

Revenue And Test Volume Growth

Strong growth in diagnostic revenue and test volume indicates expanding utilization of Biodesix’s core clinical testing services. Continued adoption can improve operating leverage, strengthen commercial relevance with providers, and support durable revenue growth as the installed physician base develops.

High Gross Margins And Improving Losses

Sustained gross margins above 80% provide a strong economic foundation for the testing business, while narrower losses show progress toward operating leverage. If revenue growth continues, this margin profile could allow incremental volume to translate into better profitability over time.

Clinical Validation And Health System Adoption

Health system implementations and independent clinical evidence can make Biodesix testing more embedded in routine care pathways. Greater integration with pulmonology and primary care workflows may support recurring utilization, improve physician confidence, and strengthen the company’s competitive position.

Bears Say

High Leverage And Thin Equity Cushion

The company’s debt burden is large relative to its equity base, leaving limited balance-sheet protection if operating performance weakens. High leverage can restrict strategic flexibility, increase dependence on financing, and make the path to sustainable growth more vulnerable to execution setbacks.

Ongoing Cash Consumption

Biodesix continues to consume cash while funding operations and investment, so growth has not yet translated into internal cash generation. Until profitability improves, the business may require external funding, limiting capital-allocation flexibility and increasing financial pressure over the next several quarters.

Sales Capacity And Commercial Execution Risk

A sales-led model remains exposed to hiring, retention, training, and ramp execution. Below-plan field capacity can delay physician acquisition and testing growth, while newly hired representatives require time before contributing, making near-term commercial expansion dependent on successful workforce recovery.

Biodesix News

Biodesix price target lowered to $34 from $38 at H.C. Wainwright

H.C. Wainwright analyst Yi Chen lowered the firm’s price target on Biodesix (BDSX) to $34 from $38 and keeps a Buy rating on the shares. The company reported a sales

3d agoBDSX

Biodesix price target lowered to $30 from $40 at Lake Street

Lake Street lowered the firm’s price target on Biodesix (BDSX) to $30 from $40 and keeps a Buy rating on the shares. Biodesix reported Q3 revenue that missed the firm’s

6d agoBDSX

Biodesix price target lowered to $34 from $40 at TD Cowen

TD Cowen lowered the firm’s price target on Biodesix (BDSX) to $34 from $40 and keeps a Buy rating on the shares. The firm updated its model following Q3 results

6d agoBDSX

Biodesix Announces Departure of Chief Commercial Officer

An update from Biodesix ( ($BDSX) ) is now available. On November 2, 2026, Biodesix, Inc. agreed that the employment of Chief Commercial Officer Kieran O’Kane would end effective that

6d ago8K BDSX

Biodesix sees FY26 revenue $101M-$103M, consensus $111.82M

Sees gross margins of approximately 80%. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on TipRanks >> Read

6d agoBDSX EARNINGS

Biodesix reports Q3 EPS (75c) vs. ($1.16) last year

Reports Q3 revenue $24.0M, consensus $27.49M. Diagnostic Testing revenue grew 16% year-over-year with test volumes up 24%, while gross margin remained flat at 81%. “Biodesix (BDSX) delivered another quarter of

6d agoBDSX EARNINGS

Biodesix price target raised to $40 from $30 at TD Cowen

TD Cowen raised the firm’s price target on Biodesix (BDSX) to $40 from $30 and keeps a Buy rating on the shares. The firm adjusted targets in the diagnostics space

1M agoBDSX

Biodesix price target raised to $38 from $27 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Biodesix (BDSX) to $38 from $27 and keeps a Buy rating on the shares. The company’s new tumor-informed and tumor-naive Molecular Residual

1M agoBDSX

Biodesix advances two programs for Molecular Residual Disease monitoring

Biodesix (BDSX) announced strategic progress in two collaborative programs for tumor-informed and tumor-naive Molecular Residual Disease – or MRD – solutions intended to support cancer centers and clinical laboratories. Both

1M agoBIO TMO

Craig-Hallum sees potential for confusion after CMS fee schedule

Craig-Hallum says the Centers for Medicare and Medicaid Services last night published the proposed 2027 clinical laboratory fee schedule, which sets Medicare rates for many lab tests. While the impact

1M agoGH NEO

Biodesix Earnings Call Highlights Rapid Growth Path

Biodesix, Inc. (($BDSX)) has held its Q2 earnings call. Read on for the main highlights of the call. Biodesix’s latest earnings call struck an optimistic tone as management highlighted robust

2M agoBDSX

Biodesix price target raised to $35 from $27 at Canaccord

Canaccord raised the firm’s price target on Biodesix (BDSX) to $35 from $27 and keeps a Buy rating on the shares. The firm said they the company reported 2Q26 results

3M agoBDSX

Biodesix Shareholders Approve Directors and Governance Measures

An announcement from Biodesix ( ($BDSX) ) is now available. At its 2026 annual meeting of stockholders held on May 19, 2026, Biodesix investors elected two Class III directors, Jean

5M ago8K BDSX

Biodesix Faces Mounting Reimbursement and Enforcement Risks as Evolving Payer Policies Threaten Revenue Stability

Biodesix, Inc. (BDSX) has disclosed a new risk, in the Costs category. Biodesix, Inc. faces heightened uncertainty as evolving payer reimbursement policies, stricter claims reviews, and shifting healthcare enforcement priorities

6M agoBDSX

BDSX FAQ

What was Biodesix’s price range in the past 12 months?

Biodesix lowest stock price was $5.26 and its highest was $31.97 in the past 12 months.

What is Biodesix’s market cap?

Biodesix’s market cap is $111.11M.

When is Biodesix’s upcoming earnings report date?

Biodesix’s next earnings report is estimated for Mar 16, 2027 (not yet confirmed), which is in 124 days.

How were Biodesix’s earnings last quarter?

Biodesix released its earnings results on Nov 05, 2026. The company reported -$0.75 earnings per share for the quarter, missing the consensus estimate of -$0.748 by -$0.002.

Is Biodesix overvalued?

According to Wall Street analysts Biodesix’s price is currently Undervalued.

Does Biodesix pay dividends?

Biodesix does not currently pay dividends.

What is Biodesix’s EPS estimate?

Biodesix’s EPS estimate is -0.63.

How many shares outstanding does Biodesix have?

Biodesix has 11,088,511 shares outstanding.

What happened to Biodesix’s price movement after its last earnings report?

Biodesix reported an EPS of -$0.75 in its last earnings report, missing expectations of -$0.748. Following the earnings report the stock price went down -57.006%.

Which hedge fund is a major shareholder of Biodesix?

Hedge funds hold Biodesix shares: the largest hedge-fund position in Biodesix is 70,140,531 shares, and hedge funds increased their holdings by 127.3K shares last quarter.

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Biodesix Stock Smart Score

Outperform

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Biodesix

Biodesix, Inc. is a data-driven diagnostic solutions provider operating across the United States. Its primary focus includes a comprehensive suite of blood-based lung tests, marketed as the Nodify Lung Nodule Risk Assessment (which includes Nodify XL2 and Nodify CDT). These assessments enable clinicians to evaluate the risk of lung cancer in patients with suspicious nodules, aiding in the reclassification of malignancy risk and guiding appropriate treatment pathways. Beyond risk assessment, Biodesix offers additional lung cancer diagnostics such as GeneStrat ddPCR, which detects specific tumor mutations, and VeriStrat, which gauges the patient's immune system status. Both are crucial for establishing prognosis and informing treatment plans. Another offering is the GeneStrat NGS (Next-Generation Sequencing) test, a rapid, blood-based sequencing solution providing results within 72 hours. Through a partnership with Bio-Rad Laboratories, Inc., Biodesix also provides COVID-19 testing services under its Biodesix WorkSafe program, featuring the Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 Total Ab test, an antibody assay for detecting a B-cell immune response indicating recent or prior infection. Furthermore, the company extends its expertise to biopharmaceutical companies, offering diagnostic and clinical research services, alongside clinical trial testing. It also actively discovers, develops, and commercializes companion diagnostics. Originally incorporated as Elston Technologies, Inc. in 2005, Biodesix, Inc. maintains its headquarters in Boulder, Colorado.

Biodesix (BDSX) Earnings & Revenues

Historic Earnings Reports

BDSX Earnings Call

Q3 2026

0:00 / 0:00

Earnings Call SentimentPositive

The call had a mixed but overall positive tone. Biodesix reported solid year-over-year revenue, diagnostic testing volume, margin and adjusted EBITDA improvements, continued clinical validation, expanding health system integrations and progress in digital diagnostics and MRD programs. These positives were tempered by results falling short of expectations, reduced sales capacity, primary care seasonality, lower development services revenue, a 6% decline in average revenue per test and a modest normalized fourth-quarter growth outlook. Management characterized the main issues as execution and timing challenges rather than changes in demand or market opportunity.

View all BDSX earnings summaries

BDSX Stock 12 Month Forecast

Average Price Target

$32.60▲(222.13% Upside)

Past 12 Months12 Month ForecastFeb2026Nov2026

High$35.00

Average$32.60

Low$30.00

Detailed Analyst Forecast >

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	6	1	15
Technical Analysis	6	1	3
Moving Averages	0	0	12

Technical Analysis >

Similar Stocks

Stocks similar to BDSX
Company	Price & Change	Follow
VNRXVolitionRX
PRPOPrecipio
BNRBurning Rock Biotech
SERASera Prognostics

Compare BDSX Stocks >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft